BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 14570729)

  • 1. Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer.
    Shpitz B; Klein E; Buklan G; Neufeld D; Nissan A; Freund HR; Grankin M; Bernheim J
    Gut; 2003 Nov; 52(11):1598-601. PubMed ID: 14570729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of colon cancer and modulation of aberrant crypt foci, cell proliferation, and apoptosis by retinoids and NSAIDs.
    Pereira MA
    Adv Exp Med Biol; 1999; 470():55-63. PubMed ID: 10709674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant crypt foci in human colons: distribution and histomorphologic characteristics.
    Shpitz B; Bomstein Y; Mekori Y; Cohen R; Kaufman Z; Neufeld D; Galkin M; Bernheim J
    Hum Pathol; 1998 May; 29(5):469-75. PubMed ID: 9596270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Aberrant crypt foci as biomarkers in chemoprevention for colorectal cancer].
    Katsuki S; Oui M; Takayama T; Takahashi Y; Shuichi N; Niitsu Y
    Nihon Geka Gakkai Zasshi; 1998 Jun; 99(6):379-84. PubMed ID: 9695076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of aspirin and metformin combination therapy in patients with rectal aberrant crypt foci: a double-blinded randomized controlled trial.
    Higurashi T; Arimoto J; Ashikari K; Takatsu T; Misawa N; Yoshihara T; Matsuura T; Fuyuki A; Ohkubo H; Nakajima A
    BMC Cancer; 2020 Oct; 20(1):1043. PubMed ID: 33121471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant crypt foci in patients with colorectal cancer.
    Roncucci L; Modica S; Pedroni M; Tamassia MG; Ghidoni M; Losi L; Fante R; Di Gregorio C; Manenti A; Gafa L; Ponz de Leon M
    Br J Cancer; 1998 Jun; 77(12):2343-8. PubMed ID: 9649156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemopreventive effect of aspirin on growth of aberrant crypt foci in rats.
    Shpitz B; Bomstein Y; Kariv N; Shalev M; Buklan G; Bernheim J
    Int J Colorectal Dis; 1998; 13(4):169-72. PubMed ID: 9810521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression.
    Wargovich MJ; Jimenez A; McKee K; Steele VE; Velasco M; Woods J; Price R; Gray K; Kelloff GJ
    Carcinogenesis; 2000 Jun; 21(6):1149-55. PubMed ID: 10837003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant crypt foci in patients with neoplastic and nonneoplastic colonic disease.
    Bouzourene H; Chaubert P; Seelentag W; Bosman FT; Saraga E
    Hum Pathol; 1999 Jan; 30(1):66-71. PubMed ID: 9923929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin: still learning about the wonder drug.
    Hawk ET; Viner JL
    Gut; 2003 Nov; 52(11):1535-6. PubMed ID: 14570718
    [No Abstract]   [Full Text] [Related]  

  • 11. Lack of chemoprevention of dietary Agaricus blazei against rat colonic aberrant crypt foci.
    Ziliotto L; Barbisan LF; Rodrigues MA
    Hum Exp Toxicol; 2008 Jun; 27(6):505-11. PubMed ID: 18784204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rectal aberrant crypt foci (ACF) as a predictor of benign and malignant neoplastic lesions in the large intestine.
    Kowalczyk M; Orłowski M; Klepacki Ł; Zinkiewicz K; Kurpiewski W; Kaczerska D; Pesta W; Zieliński E; Siermontowski P
    BMC Cancer; 2020 Feb; 20(1):133. PubMed ID: 32075595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant crypt foci in colorectal carcinogenesis. Cell and crypt dynamics.
    Roncucci L; Pedroni M; Vaccina F; Benatti P; Marzona L; De Pol A
    Cell Prolif; 2000 Feb; 33(1):1-18. PubMed ID: 10741640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eicosapentaenoic acid (EPA) efficacy for colorectal aberrant crypt foci (ACF): a double-blind randomized controlled trial.
    Higurashi T; Hosono K; Endo H; Takahashi H; Iida H; Uchiyama T; Ezuka A; Uchiyama S; Yamada E; Ohkubo H; Sakai E; Maeda S; Morita S; Natsumeda Y; Nagase H; Nakajima A
    BMC Cancer; 2012 Sep; 12():413. PubMed ID: 22992267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenic switch in earliest stages of human colonic tumorigenesis.
    Shpitz B; Gochberg S; Neufeld D; Grankin M; Buklan G; Klein E; Bernheim J
    Anticancer Res; 2003; 23(6D):5153-7. PubMed ID: 14981982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms.
    Sinicrope FA; Velamala PR; Song LMWK; Viggiano TR; Bruining DH; Rajan E; Gostout CJ; Kraichely RE; Buttar NS; Schroeder KW; Kisiel JB; Larson MV; Sweetser SR; Sedlack RR; Sinicrope SN; Richmond E; Umar A; Della'Zanna G; Noaeill JS; Meyers JP; Foster NR
    Cancer Prev Res (Phila); 2019 Nov; 12(11):821-830. PubMed ID: 31484660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression.
    Tessitore L; Davit A; Sarotto I; Caderni G
    Carcinogenesis; 2000 Aug; 21(8):1619-22. PubMed ID: 10910967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histomorphology of aberrant crypt foci in colorectal carcinoma.
    Norlida AO; Phang KS
    Malays J Pathol; 2010 Dec; 32(2):111-6. PubMed ID: 21329182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of Low Doses of Acetylsalicylic Acid on the Occurrence of Rectal Aberrant Crypt Foci.
    Kowalczyk M; Sigorski D; Dyśko Ł; Zieliński E; Zupanovich Lucka D; Klepacki Ł
    Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant crypt foci and beta-catenin accumulated crypts; significance and roles for colorectal carcinogenesis.
    Mori H; Yamada Y; Kuno T; Hirose Y
    Mutat Res; 2004 May; 566(3):191-208. PubMed ID: 15082237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.